JUUL vs. cigarettes: which delivers nicotine faster?
NCT ID NCT04053868
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how nicotine enters the body when people use JUUL e-cigarettes compared to smoking regular tobacco cigarettes. Seventeen healthy adult smokers took part, and researchers measured nicotine levels and heart rate after each product. The goal was to understand the differences in nicotine delivery, not to test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
17 people
The number who actually took part.
- Started
-
Dec 2019
- Finished
-
Mar 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy on the basis of medical history and limited physical examination, as described below: * \- Heart rate \< 105 beats per minute (bpm) * \- - Considered out of range if both machine and manual readings are above/below these thresholds. * \- Systolic Blood Pressure \< 160 and \> 90\* * \- Diastolic Blood Pressure \< 100 and \> 50\* * Age: \>= 21 \& \<=70 years old * Body Mass Index (BMI) \<= 38.0 (at PI's discretion for higher BMI if no other concurrent health issues) * Willingness to avoid combusted marijuana up to 48 hours before each study visit * Nicotine strength of e-liquid of usual e-cigarette \> 0 mg/ml * Group 1 Experienced E-cigarette users * \- Current use of tobacco cigarettes (\<5 cigarettes per day) * \- Current e-cigarette use at least 15 days out of the past 30 days of a non-mod e-cigarette * Group 2 Primary Tobacco cigarette users: * \- Currently smoking \>= 5 cigarettes per day * \- Current e-cigarette use must be \< 5 times per month * Saliva cotinine \>=50 ng/ml or urine cotinine and/or NicAlert=6 * Must have a smart phone, computer, or tablet and internet access (for remote procedures) Exclusion Criteria: * Medical * \- Heart disease * \- Seizures * \- Cancer * \- Thyroid disease (okay if controlled with medication) * \- Diabetes * \- Hepatitis B or C or Liver disease * \- Glaucoma * \- Kidney disease or urinary retention * \- History of stroke * \- An ulcer in the past year * \- Active use of an inhaler for Asthma or Chronic Obstructive Pulmonary Disease (COPD) * Psychiatric conditions * \- Current or past schizophrenia, and/or current or past bipolar disorder * \- Major depression, current or within the past year * \- Major personality disorder * \- Participants with current or past minor or moderate depression and/or anxiety disorders will be reviewed by the principal investigator (PI) and/or medical monitor and considered for inclusion * \- History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per PI's or medical monitor's approval * Drug/Alcohol Dependence * \- Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program * \- Positive toxicology test for illicit drugs at the screening visit (Tetrahydrocannabinol (THC) \& prescribed medications okay) * \- Opioid replacement therapy (including methadone, buprenorphine, or other) * Psychiatric medications * \- Current regular use of any psychiatric medications is exclusionary, with the exception of Selective Serotonin Reuptake Inhibitor (SSRI) and serotonin-norepinephrine reuptake Inhibitor (SNRI) and current evaluation by the PI and/or medical monitor that the participant is otherwise healthy, stable, and able to participate * Medications * \- Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers) * \- Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs) * \- Concurrent use of nicotine-containing medications * \- Any stimulant medications (example: Adderall) generally given for attention deficit hyperactivity disorder (ADHD) treatment * Use of Other Tobacco Products (OTP) * \- Any of the following products in combination more than 15 times in the past month * \- - smokeless tobacco (snus, oral snuff, chewing tobacco) * \- - pipes * \- - cigars, cigarillos, little cigars * \- - blunts, spliffs * \- - hookah * Other/Misc. Chronic Health Conditions * Fainting (within the last 30 days) * Other "life threatening illnesses" as per PI's or medical monitor's discretion * Pregnancy * \- Pregnancy (self-reported and urine pregnancy test) * \- Breastfeeding (determined by self-report) * Concurrent participation in another clinical trial (at PI's discretion) * Inability to read and write in English * Planning to quit smoking or vaping within the next 60 days * Recent onset or change (worsening) in cough, fever and/or abdominal symptoms (vomiting or pain) in the past two weeks * Diagnosis of pneumonia in the past 3 months * Uncomfortable with blood draws * Known allergy to propylene glycol or vegetable glycerin
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for E-cigarettes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
Zuckerberg San Francisco General Hospital
San Francisco, California, 94110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Text messages and clinic prompts may boost smoking cessation
- Teens vs. vaping: can peer power break the habit?
- Will Acted-Out vaping stories persuade teens to stay away?
- Can a 30-Minute online session spark quit motivation in smokers with chronic pain?
- AI-Powered texts aim to help smokers beat the habit
- Salt caves may boost the power of yoga breathing for smokers' lungs